In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Off-Label Info OK: So What?

Executive Summary

One of the most controversial issues coming out of the recently concluded legislative battle over reforming the FDA involved expanding medical companies' abilities to promote off-label uses of their products. Yet in the end, the ultimate impact of this reform appears to be negligible.
Advertisement

Related Content

DTC Implications: FDA Calls Foul on Magic Johnson Promotional DVD
Watch What You Eat: A PhRMA Marketing Code Q&A
Optical Illusion: Why Genentech Is Winning the Fight Over Lucentis
Bum Steer: Long Term Care Pharmacies Take CMS to Court Over "Steering"

Topics

Advertisement
UsernamePublicRestriction

Register

IV000594

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel